Unveiling BioHeartland Indiana: A New Era in Global Bioscience Leadership

On June 22, 2026, Indiana made waves at the BIO International Convention held in San Diego by introducing its newly branded bioscience identity, "BioHeartland Indiana." This initiative is the brainchild of the CEOs of Indiana Corporate Partnership, highlighting the state's commitment to becoming a key player in the global bioscience arena.

A Century of Innovation

For over a hundred years, Indiana has been at the forefront of bioscience innovation, encompassing human health, animal health, and plant sciences. The region has pioneered advancements particularly seen in the GLP-1 revolution, which reflects how research, development, and manufacturing can come together seamlessly in one ecosystem. With renowned companies like Eli Lilly & Company and Elanco Animal Health headquartered here, Indiana is not just another location; it's a thriving nucleus of bioscience ingenuity.

Uniting Under One Identity

The introduction of BioHeartland Indiana seeks to clarify and unify the state’s significant contributions to bioscience. Melina Kennedy, CEO of the CEOs of Indiana Corporate Partnership, expressed the importance of this shared identity. She emphasized that while Indiana has been a powerhouse in helping develop bioscience solutions, the story of its innovation prowess has not been effectively communicated. The new identity, BioHeartland, aims to ensure that investors and talent recognize the vast potential and collaborative spirit that Indiana embodies.

Significant Economic Impact

The bioscience sector in Indiana generates over $100 billion of economic activity, a testament to its robust network of industries. The region boasts four R1 universities, the nation’s largest medical school, and the Indiana Bioscience Research Institute, all contributing to an impressive achievement of producing three times the national average of issued patents. This collaborative ecosystem fosters an environment conducive to innovation and commercial success.

A Billion-Dollar Commitment

This unveiling comes on the heels of Governor Mike Braun's substantial $1 billion investment aimed at accelerating the growth of Indiana’s life sciences companies over the next decade. As Vince Wong, CEO of BioCrossroads, notes, the term "BioHeartland Indiana" will signify an open landscape ripe for scientific exploration, innovation, and industry collaboration. This unified image is intended to position Indiana alongside prominent bioscience hubs like Boston and the Research Triangle in North Carolina.

The Role at the BIO International Convention

BioHeartland Indiana didn’t just launch its identity; it actively showcased it through its presence at the 2026 BIO International Convention. Various partners encompassing Eli Lilly, Elanco, and several innovation districts participated, presenting a united front and engaging attendees with insights into Indiana’s life sciences dynamics. They ensured that visitors at Booth 3134 delved deeper into the resources, infrastructure, and capabilities that bolster Indiana's life sciences momentum.

Leading the Charge

The BioHeartland initiative amplifies Indiana's strengths while shining a spotlight on the key figures, institutions, and partnerships that propel the state’s life sciences sector forward. From traditional agricultural practices to cutting-edge medical research, the themes of collaboration and innovation resonate throughout the new identity.

As this journey unfolds, it is clear that BioHeartland Indiana is not just a brand—it's a promise to foster the next wave of biotechnological advancements. With increased public awareness and engagement from stakeholders, Indiana is poised to lead the world in delivering life-changing solutions across human, animal, and plant health. Discover more about this ambitious initiative at INBioHeartland.com.